Co-dergocrine mesylate

Generic Medicine Info
Acute or chronic psychosis. Concurrent use w/ strong CYP3A4 inhibitors.
Special Precautions
Patient w/ severe bradycardia. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery.
Adverse Reactions
Nervous: Headache, dizziness. CV: Bradycardia, tachycardia, orthostatic hypotension. GI: Abdominal cramps, nausea, vomiting, anorexia. Resp: Nasal congestion. Ophthalmologic: Blurred vision. Dermatologic: Rash, skin flushing.
Drug Interactions
May reduce plasma concentration of ticlopidine. Enhanced serotonergic effect w/ MAOIs, linezolid. May enhance the adverse effect of antipsychotic agents, metoclopramide. Enhanced vasoconstriction w/ beta-blockers. May diminish the vasodilatory effect of nitroglycerin.
ATC Classification
C04AE04 - dihydroergocristine ; Belongs to the class of ergot alkaloids. Used as peripheral vasodilators.
Disclaimer: This information is independently developed by CIMS based on co-dergocrine mesylate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in